R82913
R82913 (9-Cl-TIBO) is a potent and high selective inhibitor of HIV-1 reverse transcriptase with antiviral activity on both an RNA template (negative strand synthesis) and a DNA template (positive strand synthesis). R82913 inhibits the replication of different strains of HIV-I in CEM cells with a median IC50 value of of 0.15 μM.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 126347-69-1
- 화학식: C16H20ClN3S
- 분자량:321.87
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| C8166 | EC50 |
0.002 μM
Compound: 1c (R 82913)
|
Inhibitory activity against HIV-111B in C8166 cells
Inhibitory activity against HIV-111B in C8166 cells
|
10.1016/0960-894X(95)00203-6 |
| C8166 | CC50 |
34 μM
Compound: TIBO R-82913
|
Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line
Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line
|
10.1016/0960-894X(95)00257-T |
| C8166 | IC50 |
0.0015 μM
Compound: TIBO R-82913
|
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
|
10.1016/0960-894X(95)00257-T |
| C8166 | EC50 |
0.002 μM
Compound: R-82913
|
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
|
10.1016/S0960-894X(97)00022-X |
| CEM-SS | CC50 |
>10000 nM
Compound: TIBO R-82913
|
Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.
Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.
|
[PMID: 7473595] |
| CEM-SS | IC50 |
>10000 nM
Compound: TIBO R-82913
|
Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells
Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells
|
[PMID: 7473595] |
| CEM-SS | CC50 |
35 μM
Compound: R-82913
|
Tested for the cytotoxicity against CEM-SS cells (determined by the inhibition of [3H]-thymidine uptake)
Tested for the cytotoxicity against CEM-SS cells (determined by the inhibition of [3H]-thymidine uptake)
|
10.1016/S0960-894X(01)81224-5 |
| CEM-SS | IC50 |
0.055 μM
Compound: R-82913
|
Tested for the inhibition of HIV-1 in CEM-SS cells measured using Syncytial assay
Tested for the inhibition of HIV-1 in CEM-SS cells measured using Syncytial assay
|
10.1016/S0960-894X(01)81224-5 |
| MOLT-4 | IC50 |
0.19 μM
Compound: TIBO R-82913
|
Anti-HIV activity against HIV-1 in Molt-4 cells using 7-day infective assay
Anti-HIV activity against HIV-1 in Molt-4 cells using 7-day infective assay
|
[PMID: 7506311] |
| MOLT-4 | IC50 |
19 μM
Compound: TIBO R-82913
|
Tested for cytotoxicity in Molt-4 cells by XTT assay
Tested for cytotoxicity in Molt-4 cells by XTT assay
|
[PMID: 7506311] |
| MT4 | EC50 |
33 nM
Compound: 2
|
Effective concentration of the compound to inhibit HIV-1 replication in HIV-infected MT-4 cells
Effective concentration of the compound to inhibit HIV-1 replication in HIV-infected MT-4 cells
|
[PMID: 15771411] |
| MT4 | IC50 |
0.039 μM
Compound: 8b
|
Ability to block replication of HIV-1 virus in mock infected MT-4 cells
Ability to block replication of HIV-1 virus in mock infected MT-4 cells
|
[PMID: 1956037] |
| MT4 | IC50 |
0.034 μM
Compound: 1a
|
Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1
|
[PMID: 7877144] |
| MT4 | IC50 |
0.042 μM
Compound: 2
|
Compound was tested for its anti HIV-1 activity in MT-4 cells.
Compound was tested for its anti HIV-1 activity in MT-4 cells.
|
10.1016/S0960-894X(01)80460-1 |
Chemical Information
-
CAS No. 126347-69-1
-
분자량 321.87
-
화학식 C16H20ClN3S
-
SMILES
S=C1N2C3=C(C=C(C=C3N1)Cl)CN([C@H](C2)C)C/C=C(C)\C
-
Synonyms
9-Cl-TIBO
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
순도&문서
References
[1]. White EL, et al. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257-66. [Content Brief]
[2]. Larder BA. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992 Dec;36(12):2664-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)